RXST - NASDAQ
RxSight, Inc.
$4.79
-2.3%RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
At a Glance
Live SnapshotRxSight, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
RxSight, Inc. Income Statement
RXST • NASDAQ
| RxSight, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
134.5M | 139.9M | 89.1M | 49M | 22.6M | 14.7M | 2.2M | |
GROSS PROFIT | |||||||
(31.5M) | (41M) | (35.3M) | (27.7M) | (18.1M) | (13M) | (4.1M) | |
103M | 98.9M | 53.8M | 21.3M | 4.5M | 1.7M | -1.8M | |
OPERATING INCOME | |||||||
(151.2M) | (135.8M) | (103.9M) | (84.6M) | (57.3M) | (37.1M) | (44.3M) | |
(112.6M) | (101.4M) | (74.8M) | (58.7M) | (32.8M) | (15.2M) | (15.2M) | |
(38.5M) | (34.4M) | (29.1M) | (26M) | (24.5M) | (21.9M) | (29.6M) | |
-48.2M | -36.9M | -50.1M | -63.3M | -52.8M | -35.4M | -46.1M | |
PRE-TAX INCOME | |||||||
(40K) | (21K) | (3.3M) | (4.9M) | (3.7M) | (510K) | (26K) | |
2.5M | 9.5M | 3.3M | -3.4M | -3.6M | 33K | 2.3M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -521K | |
9.3M | 9.5M | 1.5M | -3.4M | 4.1M | 63M | 172.3M | |
-38.9M | -27.4M | -48.6M | -66.7M | -48.7M | 27.6M | 126.2M | |
NET INCOME | |||||||
(66K) | (50K) | (20K) | (9K) | (8K) | (57K) | (24K) | |
-38.9M | -27.5M | -48.6M | -66.8M | -48.7M | 27.6M | 126.2M |
SEC Filings
RXST - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | March 19, 2026 | January 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 11, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 22, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 18, 2025 | 2025 |
Related Guides
Continue your RXST research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.